

VZCZCXRO4138  
RR RUEHCN RUEHGH RUEHVC  
DE RUEHGZ #0941/01 2720248  
ZNR UUUUU ZZH  
R 290248Z SEP 06  
FM AMCONSUL GUANGZHOU  
TO RUEHC/SECSTATE WASHDC 4179  
INFO RUEHOO/CHINA POSTS COLLECTIVE  
RUCPDOG/USDOC WASHDC  
RUEAIIA/CIA WASHDC  
RUEKJCS/DIA WASHDC  
RHHMUNA/HQ USPACOM HONOLULU HI

UNCLAS SECTION 01 OF 02 GUANGZHOU 030941

SIPDIS

SENSITIVE  
SIPDIS

BEIJING FOR CG  
STATE FOR CA/VO, EB, AND EAP/CM  
USDOC FOR 4420/ITA/MAC/MCQUEEN  
USPACOM FOR FPA

E.O. 12958: N/A

TAGS: [CVIS](#) [ECON](#) [ETRD](#) [CH](#)

SUBJECT: Mindrays! - Consular Outreach to Shenzhen Mindray in  
Shenzhen. Part 3 of 3.

REF: A) GUANGZHOU 30782 B) GUANGZHOU 30894 C) GUANGZHOU 031368 D)  
GUANGZHOU 018161

THIS DOCUMENT IS SENSITIVE BUT UNCLASSIFIED. IT SHOULD NOT BE  
DISSEMINATED OUTSIDE OF U.S. GOVERNMENT CHANNELS OR IN ANY PUBLIC  
FORUM WITHOUT THE WRITTEN CONCURRENCE OF THE ORIGINATOR. IT SHOULD  
NOT BE POSTED ON THE INTERNET.

1. (SBU) SUMMARY: At an August 25 meeting with Congenoffs, Shenzhen  
Mindray officials - whose company is a fast-growing producer of  
low-cost medical diagnostic equipment - emphasized the importance of  
U.S. trade shows in their overall sales growth. Despite Mindray's  
heavy research and development focus, its products do not appear on  
the technology alert list (TAL); most of the company's employees are  
of little TAL concern. Note: This is the third of three cables about  
how the consular section is reaching out to Shenzhen companies to  
better understand the South China business environment and visa  
needs. (see Refs A and B). END SUMMARY

2. (U) Shenzhen Mindray is a Chinese medical device company that has  
received significant U.S. funding through venture capital firms in  
the United States. Although Mindray executives told us that U.S.  
investors had cashed out in 1999, the company does plan to open a  
new R&D center in Seattle and will seek to raise funds for expansion  
by offering an initial public offering on the New York Stock  
Exchange in 2007. Recent press reports confirm Mindray will trade  
under the symbol "MR" and will seek to raise USD 276 million in its  
IPO.

Shenzhen Mindray - More Science than Science Fiction  
-----

3. (U) Shenzhen Mindray, located in the glittering NanShan district  
of Shenzhen where the towering headquarters of ZTE (Ref C) casts a  
shadow on Mindray's smaller office, is a bio-medical electronics  
company with a 15 year history. Beginning in 1991 as a humble  
distributor of patient monitors in China, company founders sought  
venture capital funding from the United States and aggressively  
reinvested revenues from previous years into research and  
development. Today, the firm has its own lines of medical  
diagnostic equipment; it designs, manufactures, and markets patient  
monitors, ultrasound machines, and clinical laboratory equipment  
such as hematology and urine analyzers. Mindray recently entered  
the anesthesia machine market. Mindray markets under its own name  
but also serves as an OEM manufacturer for foreign medical product  
companies such as Datascope and BCI.

4. (SBU) Jie Liu, Vice President of International Marketing, Sammie

Su, Marketing Manager, and Lisa Li, Deputy Manager from the President's Office told Congenoffs that Mindray's workforce consisted of 2420 employees and they emphasized that the company was primarily a medical device R&D firm. Mindray does perform all of its own manufacturing due to the narrowness of its market and the high requirements of the Food and Drug Administration and other regulatory agencies, but over 800 of its employees are engineers engaged in R&D, and 70 percent of them have graduate degrees. Marketing comprises another third of the workforce; a third of its employees work in Mindray's factory in Xili, a short drive away.

VISAS

-----

15. (SBU) Mr. Liu explained that while Mindray is making great strides in developing state-of-the-art technology in medical devices, it still cannot compete in the United States, Canada, Australia, and Western Europe with the likes of industry giants General Electric, Philips, and Siemens. Mindray thus purposefully tries to develop lower-cost, but still high-tech, products to suit its primary markets: Eastern Europe, Asia, and Latin America. Ms. Su explained that while the United States is a small market for Mindray, four large medical device trade shows held in the United States each year attract many potential purchasers from markets such as Latin America. The company's ability to send marketing and engineering teams of 12-15 people to each of these shows is crucial to its efforts.

16. (SBU) Mindray's main complaint about the visa process was that wait times are unpredictable due to administrative processing and issued visas are usually only for one entry. Ms. Su further commented that one entry visas are extremely inconvenient for company staff as they often need to transit the United States twice to visit with customers in Latin America on the same trip. A single

GUANGZHOU 00030941 002 OF 002

entry visa forces employees to take less desirable routing. (Note: Visas issued after a Mantis Special Advisory Opinion are limited to single entry, three months. End note.) Conoffs explained they understood the frustration and that the meeting would help line officers better understand travel needs.

Comment

-----

17. (SBU) Conoffs in the past have felt unease with issuing visas to applicants from Mindray without seeking a SAO, due in large part to the company's heavy emphasis on medical device research and development. After this facility tour and dialogue, Conoffs came away with the firm belief that Mindray is what it states itself to be: a manufacturer and producer of largely lower-cost, hospital-quality medical products. While high-tech in design, the products are primarily for hospital and clinical use in aiding patient diagnosis. In addition, the impending IPO on the New York Stock Exchange should make the company's plans and financing more transparent. None of Mindray's current product lines appears to be on the technology alert list. While Conoffs agreed that Mindray and its products should be monitored and were wary about Mr. Liu's unwillingness to comment on the founders backgrounds, there seems little need to perform SAOs on most applicants.

GOLDBERG